Changes in protein expression after neoadjuvant use of aromatase inhibitors in primary breast cancer: a proteomic approach to search for potential biomarkers to predict response or resistance

Bibliography

• Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;(ii):104-107
   Google Scholar
• Lonning PE. Aromatase inhibitors in breast cancer. Endocr Relat Cancer 2004;11(2):179-89
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Influence of letrozole and anastrozole on the total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20(3):751-7
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzda A, Pollak M, Anastrozole is superior to tamoxifen as first-line therapy for advance breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-67
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Sun Y, Gershanovich M, Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroup and a test of functional ability. Oncologist 2004;9(5):489-96
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV, Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for Research and Treatment of Breast Cancer Cooperative Group. J Clin Oncol 2008;26(30):4883-90
   PubMed Web of Science ®Google Scholar
• Baum M, Budzar AU, Cuzick J, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359(9324):2131-9. Erratum in: Lancet 2002;360(9344):1520
   PubMed Web of Science ®Google Scholar
• Ingle JN, Tu D, Pater JL, Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annu Oncol 2008;19(5):877-82
   PubMed Web of Science ®Google Scholar
• Normanno N, Di Maio M, De Maio E, Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12(4):721-47
   PubMed Web of Science ®Google Scholar
• Mackay A, Urruticoechea A, Dixon JM, Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9(3):R37
   PubMed Web of Science ®Google Scholar
• Chow LW, Yip AY, Loo WT, Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111(1-2):13-7
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92(3):205-16
   PubMed Web of Science ®Google Scholar
• Yamashita H, Takahashi S, Ito Y, Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009;100(11):2028-33
   Google Scholar
• Chen YY, DeVries S, Anderson J, Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer 2009;9:285
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Luo J, Outcome prediction for estrogen receptor-positive breast cabcer based on postneoadjuvant endocrine therapy tumour characteristics. J Natl Cancer Inst 2008;100(19):1380-8
   PubMed Web of Science ®Google Scholar
• Johnson D, Oppermann H, Jackson J, Induction of four proteins in chick embryo cells arsenite. J Biol Chem 1980;255:6975-80
   Web of Science ®Google Scholar
• Whelan RD, Hill BT. Differential expression of steroid receptors, hsp27, and pS2 in a series of drug resistant human breast tumour cell lines derived following exposure to antitumour drugs or to fractionated X-irradiation. Breast Cancer Res Treat 1993;26(1):23-39
   PubMed Web of Science ®Google Scholar
• Kalogeraki A, Giannikaki E, Tzardi M, Correlation of heat shock protein (HSP70) expression with cell proliferation (MIb1), estrogen receptors (ER) and clinicopathological variables in invasive ductal breast carcinomas. J Exp Clin Cancer Res 2007;26(3):367-8
   PubMed Web of Science ®Google Scholar
• Dix DJ, Allen JW, Collins BW, Targeted gene disruption of Hsp-70-2 results in failed meiosis, germ cell apoptosis, and male infertility. Proc Natl Acad Sci USA 1996;93(8):3264-8
   PubMed Web of Science ®Google Scholar
• Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 1995;64:375-401
   PubMed Web of Science ®Google Scholar
• Breton S. The cellular physiology of carbonic anhydrases. JOP 2001;2(4 Suppl):159-64
   PubMedGoogle Scholar
• Grinstein S, Rotin D, Mason MJ. Na+/H+ exchange and growth factor-induced cytosolic pH changes. Role in cellular proliferation. Biochim Biophys Acta 1989;988(1):73-97
   PubMed Web of Science ®Google Scholar
• Yarmishyn A, Child ES, Elphick LM, Differential regulation of the cyclin-dependent kinase inhibitors p21 Cip1 and p27 Kip1 by phosphorylation directed by the cyclin encoded by murine Herpesvirus 68. Exp Cell Res 2008;314:204-12
   PubMed Web of Science ®Google Scholar
• Marzouk SE, Schultz-Norton JR, Likhite VS, Rho GDP dissociation inhibitor a interacts with estrogen receptor a and influences estrogen responsiveness. J Mol Endocrinol 2007;39:249-59
   PubMed Web of Science ®Google Scholar
• Thornalley PJ. Protecting the genome: defence against nucleotide glycation and emerging role of glyoxalase I overexpression in multidrug resistance in cancer chemotherapy. Biochem Soc Trans 2003;31(6):1372-7
   PubMedGoogle Scholar
• Pikarsky E, Porat RM, Stein I, NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-6
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 2005;9(1):59-71
   PubMed Web of Science ®Google Scholar
• Goodsell DS. The molecular perspective: the ras oncogene. Oncologist 1999;4(3):263-4
   PubMedGoogle Scholar
• Downward J. Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 2003;3(1):11-22
   PubMed Web of Science ®Google Scholar
• Chen Z, Montcouquiol M, Calderon R, Jxc1/Sobp, encoding a nuclear zinc finger protein, is critical for cochlear growth, cell fate, and patterning of the organ of corti. J Neurosci 2008;28(26):6633-41
   PubMed Web of Science ®Google Scholar